The primary mediastinal lymphoma : state of the art and therapeutical perspectives
Within diffuse large B-cell lymphomas, the Primary Mediastinal Large B-Cell Lymphoma has to be considered as a separate and well-defined clinico-pathological entity. Its tendency to target young adults makes its social impact particularly significant; hence, the General Practitioner carries the responsibility for an early diagnosis. On the contrary, the extreme complexity of the available therapies makes a quick referral to specialized Clinical Centres of outmost importance, since this remains the best way to enrol as many patients as possible in therapeutic protocols. Nowadays, good clinical results and a favourable outcome are achievable, but some questions remain open. The role of radiotherapy still has to be clarified, both as a complete remission consolidation, as well as a treatment of the residual disease. Conversely, a golden standard for the second line treatment has not been clearly established.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:104 |
|---|---|
| Enthalten in: |
Recenti progressi in medicina - 104(2013), 5 vom: 07. Mai, Seite 203-8 |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Il linfoma primitivo del mediastino: stato dell'arte e prospettive terapeutiche |
|---|
| Beteiligte Personen: |
Foppoli, Marco [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.12.2013 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1701/1291.14277 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM228181828 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM228181828 | ||
| 003 | DE-627 | ||
| 005 | 20231224075332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||ita c | ||
| 024 | 7 | |a 10.1701/1291.14277 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0760.xml |
| 035 | |a (DE-627)NLM228181828 | ||
| 035 | |a (NLM)23748685 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Foppoli, Marco |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The primary mediastinal lymphoma |b state of the art and therapeutical perspectives |
| 246 | 3 | 3 | |a Il linfoma primitivo del mediastino: stato dell'arte e prospettive terapeutiche |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.12.2013 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Within diffuse large B-cell lymphomas, the Primary Mediastinal Large B-Cell Lymphoma has to be considered as a separate and well-defined clinico-pathological entity. Its tendency to target young adults makes its social impact particularly significant; hence, the General Practitioner carries the responsibility for an early diagnosis. On the contrary, the extreme complexity of the available therapies makes a quick referral to specialized Clinical Centres of outmost importance, since this remains the best way to enrol as many patients as possible in therapeutic protocols. Nowadays, good clinical results and a favourable outcome are achievable, but some questions remain open. The role of radiotherapy still has to be clarified, both as a complete remission consolidation, as well as a treatment of the residual disease. Conversely, a golden standard for the second line treatment has not been clearly established | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antibodies, Monoclonal, Murine-Derived |2 NLM | |
| 650 | 7 | |a Bleomycin |2 NLM | |
| 650 | 7 | |a 11056-06-7 |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Vincristine |2 NLM | |
| 650 | 7 | |a 5J49Q6B70F |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a Leucovorin |2 NLM | |
| 650 | 7 | |a Q573I9DVLP |2 NLM | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 700 | 1 | |a Citterio, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Donadoni, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Govi, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreri, Andrés Jm |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Recenti progressi in medicina |d 1948 |g 104(2013), 5 vom: 07. Mai, Seite 203-8 |w (DE-627)NLM000023124 |x 2038-1840 |7 nnns |
| 773 | 1 | 8 | |g volume:104 |g year:2013 |g number:5 |g day:07 |g month:05 |g pages:203-8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1701/1291.14277 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 104 |j 2013 |e 5 |b 07 |c 05 |h 203-8 | ||